Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout
Executive Summary
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
You may also be interested in...
Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
Quite A Range: Adamas Ponders $10,000-$30,000 Price Tag For Gocovri
The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.